Navigation Links
Martek to Announce Third Quarter 2010 Results
Date:8/18/2010

COLUMBIA, Md., Aug. 18 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it intends to release the results of its third quarter of fiscal 2010 on Wednesday, September 1, 2010, at approximately 4:00 p.m. Eastern Time (ET).  At 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors.  All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.

An archived webcast of the conference call will be available on the Martek's website for thirty days.  In addition, a recorded playback of the call will be available for one week and can be accessed by calling 800-633-8284 or 402-977-9140 and entering pass code 21479068.

Martek Biosciences Corporation is a leader in the innovation, development, production and sales of high-value products from microbial sources that promote health and wellness through nutrition. The company is the world's leading provider of algal DHA omega-3 with its flagship product, life'sDHA™, a sustainable and vegetarian source of algal DHA omega-3 important for brain, heart and eye health throughout life, for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing up milks. Additionally, Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products in major mass, club, drug, grocery and specialty stores and holds leading brand positions in all of its key product categories. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA™ or life'sARA™ products, visit http://www.lifesdha.com/. For more information about Amerifit Brands, visit www.amerifit.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.Contact:

Kyle StultsInvestor Relations(410) 740-0081Cassie France-KellyPublic Relations(410) 740-0081
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
2. Concord Medical Announces Second Quarter 2010 Financial Results
3. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
4. Cardica Announces Fiscal 2010 Fourth Quarter and Year End Financial Results
5. VirtuOx and Watermark Medical Announce Strategic Alliance to Expand Sleep Apnea Home Sleep Testing Solutions
6. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
7. US Oncology Announces Addition of John Osborn as EVP & General Counsel and Asif Ahmad as EVP of Technology Services
8. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
9. Medco Announces Agreement to Acquire United BioSource Corporation: A Global Medical Research and Scientific Services Leader to Advance Drug Safety and Knowledge
10. Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results
11. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
Breaking Medicine Technology:
(Date:7/25/2017)... OK (PRWEB) , ... July 25, 2017 , ... ... proud to announce the launch of their partnership to provide the Pharmacist ... the first pharmacy-focused platform in the country with the ability to develop the ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... ATM provider in the United States, today announced its partnership with financial technology ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
Breaking Medicine News(10 mins):